Preparation of olmesartan medoxomil solid dispersion with sustained release performance by mechanochemical technology

Drug Deliv Transl Res. 2022 Mar;12(3):589-602. doi: 10.1007/s13346-021-00959-w. Epub 2021 Apr 15.

Abstract

Hypertension is a common disease for human with high morbidity and mortality, and olmesartan medoxomil (OM) is widely used in the therapy of hypertension. However, poor water solubility and low bioavailability limit its widespread use. To improve the effect of OM, a ternary OM solid dispersion consisting of hydroxypropyl-β-cyclodextrin (HP-β-CD) and hydroxypropyl methylcellulose (HPMC) was prepared by mechanochemical method. The best preparation parameters were OM/HP-β-CD/HPMC-E5 with mass ratio of 1:2.6:1 and milling time of 4 h. Under the optimal preparation conditions, the solubility of the ternary solid dispersion could be increased by 12 times as compared with pure OM. Due to the addition of HPMC-E5, the solid dispersion had sustained release performance with prolonged release time of 12 h. Furthermore, in vivo study demonstrated that the prepared solid dispersion could afford significantly improved bioavailability of ~ 3-fold in comparison with pure drug. Hence, the prepared ternary solid dispersion of OM may be a promise delivery system for clinical application.

Keywords: Mechanochemistry; Olmesartan medoxomil; Oral bioavailability; Solid dispersion; Sustained release.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Hydroxypropyl-beta-cyclodextrin
  • Administration, Oral
  • Biological Availability
  • Delayed-Action Preparations
  • Humans
  • Hypertension*
  • Hypromellose Derivatives
  • Olmesartan Medoxomil
  • Particle Size
  • Solubility
  • Technology

Substances

  • Delayed-Action Preparations
  • 2-Hydroxypropyl-beta-cyclodextrin
  • Hypromellose Derivatives
  • Olmesartan Medoxomil